Control Engineering for Cancer Therapy

Cancer encompasses various diseases associated with loss of control in the mechanisms that regulate the cell numbers in a multicellular organism. It is usually caused by malfunctions in the cellular signaling pathways. Malfunctions occur in different ways and at different locations in a pathway. Consequently, therapy design should first identify the location and type of malfunction and then arrive at a suitable drug combination. Given the dynamics, feedback, and other complexities involved, systems and control approaches can be instrumental in both the identification and therapy aspects of cancer treatment.

Introduction to Molecular Biology and Cancer

Multicellular organisms such as humans are made up of about 100 trillion cells. A cell is the basic unit of life, and nothing smaller than a cell can be considered to be truly living. Each cell is like a massive factory where thousands of reactions are performed every second inside compartmentalized organelles. By far the largest organelle in a human cell is the nucleus, which contains the genetic information written using the four-letter language of DNA.

Cell division is under tight control and depends on signaling mechanisms from neighbors. Furthermore, in the absence of survival signals from neighbors, a cell will activate an intracellular suicide mechanism, apoptosis, and eliminate itself. It is this dynamic equilibrium between controlled cell proliferation and cell death that maintains the tissue architecture in adult multicellular organisms. When this dynamic equilibrium is disrupted, it leads to the formation of tumors, which are initially benign. Subsequently, these tumors can become malignant or cancerous by acquiring the ability to invade surrounding tissue. Metastases can occur as these tumors develop the ability to spread to distant sites via the blood or lymphatic system.

Genetic Regulatory Networks and Pathways

Genes (and other biological molecules such as proteins) interact with each other in a multivariate fashion. Historically, biologists have focused on experimentally studying the marginal cause-effect interactions between a small number of biological molecules, leading to what is called biological pathway information. This piecemeal approach, primarily studied using simpler organisms, has been very successful in unravelling the sequences of steps involved in metabolic processes; however, it has failed to completely elucidate the intricate cellular signaling that is associated with higher organisms such as humans. With the advent of high-throughput technologies such as microarrays (which can simultaneously provide measurements of the activity status of thousands of genes), several approaches have recently been proposed for modeling the multivariate interactions between genes, leading to what are called genetic regulatory networks. The study of these networks has been carried out using differential equations, Bayesian networks, Boolean networks, and their stochastic generalizations, the so-called probabilistic Boolean networks (PBNs). PBNs can be equivalently represented as homogenous Markov chains. By introducing external treatment as a control variable in the PBN, we obtain a controlled Markov chain or a Markov decision process. By formulating cancer treatment as the problem of moving the stationary distribution of a genetic regulatory network from an undesirable state to a desirable one, and trading off the costs involved, one can formulate an optimal control problem that can be solved using dynamic programming and its variants. One challenge with this approach is the huge amount of data needed to reliably infer a genetic regulatory network.
Combination Therapy Design Based on Pathway Information

Biological pathway information, despite its limitations, can also be useful in therapy design. In cases where feedback loops are absent, the pathway can be modeled as a digital circuit using logic gates. Computer simulation of the digital circuit can aid in identifying where in the pathway signal breakdown can occur using only input/output information. Furthermore, the effect of different anticancer drugs, whose main mechanism of action is to cut off the downstream signaling, can be superimposed on the digital circuit at the known appropriate points of intervention. Thereafter, this circuit can be used to make predictions about the efficacy of different drug combinations. See the figure below for an example.

Future Challenges in Experimental Validation

The predictions regarding combination therapy for cancer merit experimental validation, perhaps using cancer cell lines. However, experimental validation must deal with several complexities, such as (i) possible inaccuracies in the pathway model; (ii) the presence of feedback loops that have not been accounted for; (iii) the presence of multiple faults; and (iv) the heterogeneity of cancer tissue. Addressing each of these problems is a research issue in its own right and could significantly contribute to cancer treatment. Here, it is encouraging to note that issues of this type, such as uncertainty and robustness, have been extensively studied in engineering disciplines such as control theory, although adapting the ideas to the current context will still be a challenge.


With the circuit above, the efficacy of drug combinations can be predicted—shown here for six drugs and 24 possibilities for signaling breakdown (represented by the numbered gates in the left figure).

Left: Digital circuit model of the growth factor signaling pathway. The input signals are the growth factors and a brake on cell division; outputs are proteins/genes reporting on cell proliferation and programmed cell death.

Right: Effect of anticancer drugs overlaid on the circuit.